Clinical Studies

    Japanese Post-Market Cohort Study

    First posted
    Jan 13, 2017
    Identifier
    NCT03020667
    Publication Site URL
    Topic
    Official Title

    An Observational Cohort Study in Japan to Assess the Patterns of Product Use and Changes in Health Outcomes Associated With the Use of HeatSticks With the IQOS Tobacco Heating System

    Brief Summary

    The objectives and endpoints of this study will be analyzed in the study population of adults legally authorized to buy tobacco products. The study will describe the patterns of use of tobacco and nicotine containing products and self-reported health outcomes and health related events in CC (Cigarette) smokers and IQOS users in Japan. Note: The initial study record (posted to ClinicalTrials.gov) included a clinical sub-study designed to estimate population level differences in the biomarkers of exposure and clinical risk endpoints between IQOS users, CC smokers and never-smokers. However, due to low recruitment and retention of subjects, the clinical sub-study was terminated in May 2017 and the main study was terminated in March 2018. The study protocol was updated to remove the clinical sub-study objectives. This version of the study reflects the latest version of the updated study protocol.

    Summary

    Recruitment: Completed

    Study Results: Available

    Enrollment: 1124

    Study Type: Observational

    Other IDs: P1-PMC-01-JP

    Related Publications

    Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

    Post-Market Studies and Surveillance Study

    Modeling the impact of changes in tobacco use on individual disease risks

    Post-Market Studies and Surveillance Study

    Evolution of Tobacco Sales and Use Following Introduction of Heated Tobacco Products in Japan

    Post-Market Studies and Surveillance Study

    3D‐Pictogram of Risk Measures in Epidemiology

    Post-Market Studies and Surveillance Study

    A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product

    Post-Market Studies and Surveillance Study

    IQOS Use Prevalence and History of Tobacco Product Use: Findings from Surveys in Japan, Italy, and Germany

    Post-Market Studies and Surveillance Study

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.